Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC. (DXCM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
73.07(c) 73.42(c) 73.5(c) 72.74(c) 72.47(c) Last
683 257 873 855 771 425 601 910 653 853 Volume
+0.95% +0.48% +0.11% -1.03% -0.37% Change
More quotes
Financials (USD)
Sales 2018 843 M
EBIT 2018 -35,6 M
Net income 2018 -48,0 M
Finance 2018 199 M
Yield 2018 -
Sales 2019 968 M
EBIT 2019 -0,03 M
Net income 2019 -15,3 M
Finance 2019 287 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 7,24x
EV / Sales2019 6,22x
Capitalization 6 305 M
More Financials
Company
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes.Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.The company was... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
04/10DEXCOM, INC. : Free Research Report as DexCom’s Quarterly Revenues Surged 29%; T..
AC
04/04DEXCOM SCHEDULES FIRST QUARTER 2018 : 30 p.m. Eastern Time.
BU
03/30NEW REPORT FOCUSING ON REAL-TIME E-H : Real-Time E-Healthcare System Market Stud..
AQ
03/30DEXCOM : wins FDA approval for next generation of glucose monitors for diabetes
AQ
03/29DEXCOM : FDA clears Dexcom to integrate glucose monitor and insulin dosing devic..
AQ
03/29DEXCOM : FDA permits marketing of Dexcom G6 integrated continuous glucose monito..
AQ
03/29DEXCOM : wins FDA approval for next generation of glucose monitors for diabetes
AQ
03/28DEXCOM : Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All Peopl..
AQ
03/28DEXCOM : FDA Authorizes Dexcom G6 CGM - Eliminating the need for fingerstick blo..
AQ
03/27DEXCOM : FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for..
BU
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04/19China May Request Minor Restrictions for Essilor Merger, Says Luxottica Chair..
DJ
04/19LUXOTTICA : chairman says China may seek 'minor restrictions' to clear Essilor d..
RE
04/04Smith & Nephew picks new CEO who sold his last company
RE
03/12Sensirion, Medartis to raise cash in Swiss IPO boom
RE
03/12STRAUMANN : Medartis to use IPO proceeds to expand amid rising implant demand
RE
More sector news : Medical Equipment, Supplies & Distribution - NEC
Latest Tweets
04/20$DXCM New Form DEFA14A for DexCom, Inc. From our Stock News Alerts App 
04/20$DXCM New Form DEF 14A for DexCom, Inc. From our Stock News Alerts App 
04/19$DXCM Inc Dexcoms recent approval of G6 should goose revenue growth in 2018... 
04/19Insider Selling: Dexcom $DXCM Insider Sells 10,000 Shares of Stock  
04/19$DXCM New Form 4 for DexCom, Inc. From our Stock News Alerts App 
More tweets
Qtime:354
News from SeekingAlpha
04/04Premarket analyst action - healthcare 
04/02DexCom Is A Takeover Candidate - Cramer's Lightning Round (3/29/18) 
03/28INSTITUTIONAL TOP IDEAS SERIES : Deerfield Management 
03/27FDA OKs Dexcom G6 integrated CGM system 
03/23Premarket analyst action - healthcare 
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | 4-Traders
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 76,6 $
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer President, Chief Executive Officer & Director
Terrance H. Gregg Executive Chairman
Jeffrey C. Moy Senior Vice President-Operations
Quentin Blackford Chief Financial Officer
Jacob Leach Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.26.28%6 305
MEDTRONIC PLC-0.93%108 294
BAXTER INTERNATIONAL3.73%36 060
ZIMMER BIOMET HOLDINGS-8.58%22 415
TERUMO CORP15.06%21 836
HOYA CORPORATION0.54%20 451